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Abstract
Statins inhibit the proximal steps of cholesterol biosynthesis, and are linked to health benefits in various conditions,
including cancer and lung disease. We have previously investigated apoptotic pathways triggered by statins in airway
mesenchymal cells, and identified reduced prenylation of small GTPases as a primary effector mechanism leading to p53-
mediated cell death. Here, we extend our studies of statin-induced cell death by assessing endpoints of both apoptosis and
autophagy, and investigating their interplay and coincident regulation. Using primary cultured human airway smooth
muscle (HASM) and human airway fibroblasts (HAF), autophagy, and autophagosome formation and flux were assessed by
transmission electron microscopy, cytochemistry (lysosome number and co-localization with LC3) and immunoblotting (LC3
lipidation and Atg12-5 complex formation). Chemical inhibition of autophagy increased simvastatin-induced caspase
activation and cell death. Similarly, Atg5 silencing with shRNA, thus preventing Atg5-12 complex formation, increased pro-
apoptotic effects of simvastatin. Simvastatin concomitantly increased p53-dependent expression of p53 up-regulated
modulator of apoptosis (PUMA), NOXA, and damage-regulated autophagy modulator (DRAM). Notably both mevalonate
cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53
accumulation, and both cyclic pifithrin-a and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7
cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation
(autophagy). Furthermore, the autophagy response is induced rapidly, significantly delaying apoptosis, suggesting the
existence of a temporally coordinated p53 regulation network. These findings are relevant for the development of statin-
based therapeutic approaches in obstructive airway disease.
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Introduction
Apoptosis is an intrinsic cellular death response that occurs in
the face of a myriad of extracellular insults. This complex process
is the culmination of coordinately regulated intrinsic and extrinsic
pathways involving the activation of intracellular pro-apoptotic
effectors such as caspases, and modulation of pro- and anti-
apoptotic Bcl-2 family members [1]. Autophagy is a dynamic
process in which intracellular membrane structures sequester
proteins and organelles for degradation in a lytic compartment. It
is evolutionarily conserved, occuring in all eukaryotic cells [2,3].
Autophagy reprocesses cellular components, contributing to
organelle turnover and to the bioenergetic management of
starvation [4]. During autophagy, parts of the cytoplasm (including
whole organelles) are sequestered into double-membrane vesicles
called autophagosomes. Autophagosomes ultimately fuse with
lysosomes to generate single-membrane autophago-lysosomes that
mediate the degradation of their contents [5]. A number of stimuli
can induce autophagy, apoptosis or both; with concomitant
induction, in a cell stimulus dependent manner autophagy can
either protect against, or promote apoptosis, [6,7,8]. The
molecular mechanisms that determine autophagy, apoptosis and
their interaction are not fully established, but may involve
induction of autophagy genes such as Atg5 in a cell type, stimulus,
and cellular environment-specific manner.
In response to DNA damage, oncogenic activation, hypoxia or
other forms of stress, p53 acts through transcription-dependent
and -independent mechanisms to manage cellular responses that
either stop or repair genomic damage to eliminate potentially
oncogenic cells. The best-studied functions of p53 relate to its
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apoptotic function of p53 occurs both at the level of transcription,
through activation of proteins such as Puma, Noxa and Bax, and
in the cytosol by binding anti-apoptotic proteins such as Bcl-2 and
Bcl-XL [12,13]. Autophagy induction by p53 may either
contribute to cell death [6] or constitute a physiological cellular
defense response [8]. As with apoptosis, the cellular localization of
p53 modulates its impact in autophagy; cytosolic p53 inhibiting
autophagy while nuclear p53 inducing and regulating autophagy
through, for example, the transactivation of autophagy inducers
such as DRAM, which encodes a lysosomal protein [6,14,15].
In the cholesterol synthetic pathway, the inhibition of 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
prevents the conversion of HMG-CoA to mevalonate, limiting
the synthesis of cholesterol and its upstream intermediates such as
the isoprenoids, farnesyl and geranygeranyl pyrophosphate (FPP
and GGPP) [16]. Notably, FPP and GGPP are used as substrates
for the prenylation of small GTP proteins, including Rho, Ras,
Rac and Cdc42; a post-translational modification that is essential
for the activation of these signaling effectors, thus enabling their
critical roles in cell growth and survival [17,18]. HMG-CoA
reductase inhibitors such as statins can stimulate apoptosis in
divergent somatic and cancer cells [19,20]. Indeed, we recently
showed that simvastatin induces apoptosis in human primary
airway mesenchymal cells via a novel p53 dependent pathway
involving selective release of Smac/Diablo and Omi/HtrA2 [13].
Notably, a recent study using hepatocytes indicates that some
hydrophobic statins can also induce autophagy, but the precise
mechanism for this effect was not elucidated clearly [21].
Here, we investigate the impact of mevalonate cascade
inhibition on both autophagy and apoptosis, and dissect
coordinating mechanisms for an interplay between these processes
in primary human airway mesenchymal cells. Our studies indicate
a role for p53 in promoting both autophagy and apoptosis, and
reveal that autophagy is induced rapidly, providing an early
protective response to statin-induced cell stress that leads to
apoptosis.
Materials and Methods
Cell culture plasticware was obtained from Corning Costar Co.
(Canada). Cell culture media, propidium iodide (PI), simvastatin,
mevalonate, cyclic Pifithrin-a, and 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) (MTT) were obtained from
Sigma-Aldrich (Oakville, CA). Rabbit anti-human cleaved cas-
pase-9, -7, -3, poly ADP-ribose polymerase (PARP), rabbit anti-
human, PUMA, Bcl-2, Beclin-1, Atg-5, Atg-12 were purchased
from Cell Signaling (Canada). Mouse anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), rabbit anti-DRAM, and
mouse anti-p53 were obtained from Santa Cruz Biotechnologies
(USA). Rabbit anti-NOXA was obtained from Abcam (USA).
Mitotracker Red, and Lysotracker Red were obtained from
Invitrogen Molecular Probes (Canada). Casapase-GloH-3/7 assay
were purchased from Promega (USA). Rabbit-anti LC3-b, mouse-
anti BNIP3 (Bcl-2/E1B-19K-interacting protein 3), Bafilomycin
A1 (Baf-A1), 3-Methyl adenine (3-MA), were purchased from
Sigma. Mouse anti-GAPDH, and rabbit anti-HDAC were
purchased from Santa Cruz (US).
Primary HASM and HAF cell culture preparation
For all experiments we used primary cultured human airway
smooth muscle (HASM) cells and airway fibroblasts (HAF) that
were prepared from 2
nd to 4
th generation bronchi in macroscop-
ically healthy segments of resected lung specimens. After
microdissection to separate the lamina reticularis and submucosal
compartment from encircling airway smooth muscle bundle, both
HAF and HASM cells were isolated by enzymatic dissociation as
we have described [13,22,23]. All procedures were approved by
the Human Research Ethics Board (University of Manitoba, ethic
reference number:H2002:150). Cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum with antibiotic. For all experiments cells were starved in
0.5% fetal bovine serum for 48 hrs prior to all treatments, which
were also done in 0.5% fetal bovine serum. Medium was changed
every 48 hrs. For all experiments, passages 3-7 of HASM and
HAF were used.
Cell viability assay
We measured cell viability of HASM and HAF under various
treatment conditions, as we have described previously using 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
[24,25]. Relative cell viability (percent of control) was calculated
using the equation: (mean OD of treated cells/mean OD of control
cells) 6100. For each time point, the treated cells were compared
with control cells that had been treated with vehicle only (DMSO,
0.1% V/V).
Measurement of apoptosis by flow cytometry
Apoptosis was measured using the Nicoletti method [7,26].
Briefly, cells grown in 12-well plates were treated with 10 mM
simvastatin for the indicated time intervals, alone or in presence of
3-MA, or Baf-A1. After scraping, the cells were harvested by
centrifugation at 800 g for 5 min, washed once with phosphate-
buffered saline, and resuspended in hypotonic propidium iodide
lysis buffer (1% sodium citrate, 0.1% Triton X-100, 0.5 mg/ml
RNase A, 40 mg/ml propidiume iodide). Cell nuclei were
incubated for 30 min at 30uC and subsequently analyzed by flow
cytometry. Nuclei to the left of the G1 peak containing hypo-
diploid DNA were considered apoptotic.
Luminescence caspase activity assays
Luminometric assays Caspase-GloH -9 and -3/7 (Promega) were
used to measure the proteolytic activity of caspase-3/7 (DEVD-
ase), and -9 (LEHD-ase). Briefly, cells sub-cultured in 96-well plate
at 15,000 cells/well, were treated with 10 mM simvastatin with or
without inhibitors and harvested at different time points. Freshly
prepared caspase reagents containing whole protein cell lysate
extract buffer and either z-DEVD-luciferin, or z-LETD-Luciferin.
In each experiment negative control cells (treated with vehicle
only) were included. Plates were gently shaken at 300-500 rpm for
30 sec and incubated for 30 min at RT. The solution was then
transferred to a white-well plate and the luminescence of each
sample was measured using a luminometer.
Sub-cellular fractionation
Cytosolic and nuclear fractions were generated using a
digitonin-based subcellular fractionation technique at 4uC [7].
Cells were scraped, pelleted by centrifugation (800 g), then washed
(PBS pH 7.2) and re-centrifuged. Pellets were permeabilized for
5 min on ice: 3610
7 cells/mL of cytosolic extraction buffer
(250 mM sucrose, 70 mM KCl, 137 mM NaCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4 pH 7.2, 100 mM PMSF, 10 mg/
ml leupeptin, 2 mg/ml aprotinin, containing 200 mg/ml digitonin).
Plasma membrane permeabilization was confirmed by staining
with 0.2% trypan blue solution. Cells were then pelleted (700 g,
20 min), and the supernatant was removed as the cytosolic
fraction. Pellets were resuspended in the same volume of nuclear
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0.1% SDS, 1% NP-40, 100 mM PMSF, 10 mg/ml leupeptin,
2 mg/ml aprotinin), followed by pelleting at 13,000 g for 3 min at
4uC, and this second supernatant collected as the nuclear fraction.
For the detection of specific protein by immunoblotting, equal
amounts of cytosolic and pellet fractions protein (calculated from
the measured concentration of each extract) were supplemented
with 56 SDS-PAGE loading buffer, subjected to standard 15%
SDS-PAGE and transferred to nitrocellulose membranes.
Stable gene silencing: lentiviral delivery of shRNA
The ATG5, and p53 shRNA constructs were obtained from Open
Biosystems (ATG5: accession #NM_004849, clone V2LHS_195828;
p53: accession #NM_000546 clone V2LHS_93613), as inserts in the
lentiviral vector GIPZ distributed by the Manitoba Centre for
Proteomics and Systems Biology as a plasmid in E. coli (DH5a). ATG7
lentiviral particles (sc-41447-V), and control shRNA lentiviral
particles (sc-108080) were purchased from Santa Cruz Biotechnology
(US). Individual colonies were amplified in LB broth with ampicillin
(100 mg/mL), and purified using a QIAGEN Maxi-Prep Kit. A
vesicular stomatitis virus G (VSVG) pseudo-typed lentiviral vector was
made using HEK 293T cells by calcium phosphate transfection of
purified ATG5 and p53 shRNA plasmid, virus packaging vector
(8.2Dvpr), and a VSVG plasmid as described previously [13]. After 3
days the supernatant was collected and concentrated by ultra-
centrifugation. For infection, primary HASM cells were grown to
70% confluence and transduced at a MOI of 6, in the presence of
8 mg/mL polybrene (final concentration), for 2 hours. Excess viral
vectors were removed, and the transduced cells were cultured in fresh
medium for 2 days before selection for stable expression of the shRNA
by growing in culture media containing puromycin (4 mg/mL) for at
least 3 weeks. For control cells, in tandem with preparation of ATG5
and p53 shRNAi lentivirus a GIPZ vector harboring ‘‘scrambled’’
non-coding shRNA was also prepared and used to generate lentivirus
for transduction of the same primary HASM cell lines that were used
to generate ATG5 and p53-deficient stable cultures. In separate
experiments cells were directly infected with ATG7 shRNA and non-
coding shRNA using lentivirus. St a b l ec l o n e sw e r es e l e c t e du s i n g
puromycin treatment. For ATG7 studies all procedures were
performed according to manufacturer protocol (Santa Cruz Biotech-
nology, US).
Immunoblotting
To prepare protein lysates cells were washed, and protein
extracts prepared in lysis buffer (20 mM Tris-HCl (pH 7.5), 0.5%
Nonidet P-40, 0.5 mM PMSF, 100 mM b-glycerol 3-phosphate
and 0.5% protease inhibitor cocktail). After a high-speed spin
(13,000 g 610 min) supernatant protein content was determined
by Lowry protein assay, then proteins were separated by SDS-
PAGE and transferred to nylon membranes under reducing
conditions. After blocking membranes with non-fat powdered milk
and Tween 20, blots were incubated overnight with the primary
antibodies at 4uC. Primary antibodies used included: cleaved
caspase-3, -9, -7, PARP, PUMA, NOXA, p53, HDAC, LC3-b,
beclin-1, BNIP3, Atg5-12, and GAPDH. HRP-conjugated sec-
ondary antibody incubation was for 1 hr at room temperature,
and then blots were developed by enhanced chemiluminescence
(ECL) detection (Amersham-Pharmacia Biotech).
Immunocytochemistry, confocal imaging and electron
microscopy
For immunocytochemistry, HASM and HAF cells were grown
overnight on coverslips and then treated with simvastatin (10 mM)
or vehicle for 72 hrs prior to fixation (4% paraformaldehyde/
120 mM sucrose) and permeabilization (0.1% Triton X-100).
Cells were incubated with rabbit anti-LC3-b (1:250). The
fluorescent images were then observed and analyzed using an
Olympus FluoView multi-laser confocal microscope. Lysosomes
were stained with 250 nM Lysotracker Red (Invitrogen Molecular
Probes) before the cells were fixed [13].
For transmission electron microscopy (TEM), cells were fixed
(2.5% glutaraldehyde in PBS, pH 7.4) for 1 h at 4uC, and then
post-fixed in 1% osmium tetroxide before embedding in Epon.
TEM was performed with a Philips CM10, at 80 kV, on ultra-thin
sections (100 nm on 200 mesh grids) stained with uranyl acetate
and counterstained with lead citrate.
Quantitative RT-PCR for ATG5, PUMA, NOXA, and DRAM
mRNA
Total cellular RNA was isolated using the RNeasy Plus Mini Kit
(Qiagen, Mississauga, ON) then 1 mg was reverse transcribed using
the QuantiTect Reverse Transcription Kit. The abundance of
ATG5, PUMA, NOXA and DRAM mRNA were determined using
the Applied Biosystems 7500 Real-Time PCR System thermocycler
and the Power SYBR Green PCR Master Mix. Oligonucleotide
primers were as follows: ATG5: forward, 59- AGCCAATGTTG-
GAAACACCTCTGC-39; reverse, 59-TCCTTCAATCTGTTGG-
CTGTGGGA-39, PUMA:forward:59-CTGTGAATCCTGTGCT-
CTGC–39; reverse: 59- AATGAATGCCAGTGGTCACA – 39,
NOXA:forward: 59-ATTACCGCTGGCCTACTGTG–39, reverse:
59- GTGCTGAGTTGGCACTGAAA –39,D R A M : f o r w a r d :5 9-A-
TTCCAGAGGAAGAAGCAGCCCTT–39reverse: 59-ACTTGG-
CCACACATGGGTTTATGC – 39.
A dissociation curve was generated at the end of each PCR
reaction to verify that a single product was amplified. 18S rRNA,
primers 59-CGCCGCTAGAGGTGAAATTC-39 (forward) and
59-TTGGCAAATGCTTTCGCTC-39 (reverse) served as the
endogenous reference gene. The relative expression levels of
ATG5 normalised to 18S rRNA and relative to vehicle treated
controls was calculated by the equation 2
(2DDCt). The DCT value
was determined by subtracting the average 18s rRNA CT value
from the average CT value of the corresponding target transcript.
The calculation of DDCT values involves subtraction of the DCT
calibrator value (vehicle treated). For the vehicle treated samples
DDCT =0 and 2
0 equals 1. For the simvastatin treated samples,
2
2DDCT indicates the fold change in gene expression relative to
time-matched controls.
Statistical analysis
All results were expressed as mean 6 SD and were compared by
one-way or two-way ANOVA followed by Tukey’s or Bonferroni’s
post hoc test, using Graph Pad Prism 4.0. P,0.05 was considered
significant. Data were collected in triplicate from at least three cell
lines unless otherwise indicated.
Results
Mevalonate cascade inhibition induces autophagy and
apoptosis in human airway mesenchymal cells
We have shown that simvastatin, an HMG-CoA reductase
inhibitor, induces apoptosis in human airway mesenchymal cells
by depleting mevalonate cascade intermediates [13]. Because
autophagy and apoptosis may occur concurrently or sequentially
in response to the same stimulus, we investigated whether
simvastatin-induced cell death occurs in association with autoph-
agy in human airway mesenchymal cells. Ultrastructural assess-
ment using transmission electron microscopy of HASM cells
p53 in Protein Lipidation Controlled Cell Death
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increase in the formation of autophagosome-like vacuoles
(Fig. 1A,B). Importantly, we also observed apoptosis in these
experiments, consistent with the endpoints used in our previous
studies [13] (Fig. S1A–C).
In autophagy lysosomes fuse with autophagosomes to form
autophagolysosomes [7,27,28], thus, we next assessed changes in
Lysotracker Red staining after simvastatin exposure (10 mM,
72 hrs). We observed a marked increase in lysosome number in
HASM (Fig. 1C). LC3 exists in two forms: LC3-I and its lipidated
derivative LC3-II; which localizes to autophagosomal membranes
prior to their fusion with lysosomes [29]. In simvastatin-treated
HASM cells we observed increased formation of LC3-punctae, a
feature of autophagic cells (Fig. 1D, E). Furthermore, dual staining
for LC3 and lysosomes revealed that simvastatin (10 mM, 72 hrs)
induced their co-localization, an additional feature of autophago-
lysosome formation (Fig. 1F) and autophagic flux.
In both HASM and HAF we next investigated simvastatin-
induced temporal changes in LC3 lipidation and abundance of
other proteins involved in autophagosome formation. Ubiquitin-
mediated association of Atg5 and Atg12 is required to recruit other
proteins to the autophagosomal membrane and form the
autophagic vacuole [7,30,31]. Concomitantly, beclin-1 is a part
of an early complex that promotes biogenesis and growth of pre-
autophagosomal membranes [32,33]. Immunoblot data show that
in human airway mesenchymal cells, simvastatin induced
increased beclin-1, the appearance of LC3-II, and the formation
of the Atg5-12 complex within 24–48 hrs (Fig. 1G). Quantitative
densitometry of western blots for LC3 II revealed a rapid, .3.5
fold increase within 24 hours, a response maintained or that
gradually increased thereafter in HAF and HASM, respectively
(Fig. 1H). Notably, in the same samples, after 48 hrs we detected a
marked increase in BNIP3 (Fig. 1I), an atypical pro-apoptotic Bcl-
2 family member whose pro-apoptotic activity is distinct from that
of other family members [34]. These data indicate that
mevalonate cascade inhibition induced both autophagy and
apoptosis, but the accumulation of proteins markers for each
process was temporally disparate, with autophagy markers
appearing in advance of those for apoptosis.
Autophagy induced by simvastatin is blocked by
mevalonate
We reported that addition of exogenous mevalonate is sufficient
to reverse the pro-apoptotic effects of simvastatin in human airway
mesenchymal cells [13]. Thus, we tested the effect of mevalonate
addition on endpoints of both apoptosis and autophagy. Co-
treatment with mevalonate (2.5 mM) prevented both LC3-II
formation and caspase-3 activation (Fig. 2A), an effect that was
associated with reduced simvastatin-induced cell death (Fig. 2B).
Selective autophagy inhibition increases simvastatin-
induced apoptosis
Mevalonate cascade inhibition rapidly induced LC3bII forma-
tion, a marker of autophagy, while apoptosis induction was much
less marked during the same 72 hr treatment period for both
HASM and HAF (Fig. 3A&B).
Autophagy induced by some cytotoxic agents is lethal to target
cells, but can also act as a survival mechanism that provides
constituents necessary for supporting cell metabolism in various
stress conditions [7,24,35,36,37,38,39,40]. To investigate the
relationship between mevalonate cascade inhibition-induced cell
death and autophagy, we used a number of interventions to inhibit
autophagy then assessed effects on cell viability. Cells were co-
treated with simvastatin and one of two chemical inhibitors: (i)3 -
methyladenine (3-MA), a class III PI3 kinase inhibitor, and (ii)
bafilomycin-A1 (Baf-A1), a specific lysosomal vacuolar-type H
+-
ATPase pump inhibitor that blocks the fusion of autophagosomes
and lysosomes [7,27]. Dose response experiments were done for
both inhibitors to find concentrations that inhibited autophagy
without affecting viability in control HASM and HAF cells. In
HASM and HAF each inhibitor suppressed simvastatin-induced
autophagy and resulted in more rapid and significantly greater
degree of cell death (P ,0.01, Fig. 3C–F). Concomitant with
reduced viability we observed morphological features of apoptosis
(e.g., cell rounding, shrinkage, partial detachment) in HASM co-
treated with simvastatin and autophagy inhibitors (Fig. 3G).
To characterize the effects of simvastatin on autophagic flux we
assessed the impact of co-treatment with inhibitors of early (3-MA)
and late (Baf-A1) autophagy on LC3-II formation. An increase in
LC3-II protein, LC3 puncta and autophagosomes could result
from blockade of autophagy at a late stage (lysosome-autophago-
some fusion and lysosome function) [7,29]; thus we measured
LC3-II in the presence of both Baf-A1 and simvastatin in HASM
(Fig. 3H) and found LC3-II levels augmented, indicating that
simvastatin-induced-LC3-II formation was not the result of the
blockage of autophagolysosme formation. As 3-MA inhibits early
autophagy events [7]we also assessed its impact when added with
simvastatin on autophagy flux, and found it decreased simvastatin
induced LC3-II levels in HASM (Fig. 3I).
To further characterize the relationship between autophagy and
apoptosis in our experimental system we focused on other
endpoints of cell death. Baf-A1 inhibition of simvastatin-induced
autophagy resulted in increased numbers of HASM in the sub-G1
DNA compartment (P,0.01, Fig. 4A). Furthermore, we found
that pretreatment with Baf A1 significantly increased simvastatin-
induced caspase-3/-7 activity (Fig. 4B-D). Using protein immu-
noblotting we also found that autophagy inhibition, using Baf-A1,
resulted in earlier and increased simvastatin-induced cleavage of
caspases-3, -7 and -9 (Fig. 4B-D). Importantly, Baf-A1, which
targets autophagosomes-lysosome fusion, promoted the accumu-
lation of LC3-II (Fig. 4D), confirming a functional requirement for
lysosomes in simvastatin-induced autophagy.
To rule out non-selective effects of chemical inhibitors, we also
used shRNAi in HASM cells to silence Atg5 expression, which
resulted in a significant inhibition of Atg5-12 formation Fig. 5(A).
The silencing of Atg5 also accelerated apoptosis and decreased
autophagy flux, as indicated by both an increase in the cleaved
forms of caspases-3, -7 and PARP and decreased LC3-II levels
compared to cells expressing control scrambled shRNAi (Fig. 5B).
Importantly, in Atg5-silenced HASM cells simvastatin toxicity was
significantly increased (P,0.05, Fig. 5C). ATG7 shRNA (Fig. 5D)
was also used to more rigorously assess the impact of chemical
inhibitors and ATG5 silencing. In a manner similar to these
interventions, we found that ATG7 knock down increased
simvastatin-induced caspase-3 activity, PARP cleavage and cell
death (Fig. 5E&F). Collectively, our data reveal that autophagy
induced by mevalonate cascade inhibition provides an early
negative modulator signal for subsequent cellular apoptosis.
p53 is a regulator of simvastatin-induced apoptosis and
autophagy
We previously showed that apoptosis induced by mevalonate
cascade inhibition in human airway mesenchymal cells is p53-
dependent [13]. Since p53 can regulate autophagy and apoptosis
[15], we next suppressed p53 activity in HASM cells using shRNAi
or the chemical inhibitor, cyclic pifithrin-a, and measured the
impact on cell death. Regardless of the method of intervention,
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treatment with simvastatin (P,0.01, Fig. 6A, P,0.001, Fig. 6B).
We monitored the sub-cellular localization of p53 and found that
mevalonate cascade inhibition promoted its redistribution to the
nucleus after 24 hours, an effect sustained for several days
(Fig. 6C). We also assessed expression of markers of simvastatin-
Figure 2. Mevalonate co-treatment inhibits simvastatin-induced apoptosis and autophagy. (A) Protein immunoblotting of cell lysates
from HASM cells treated with 10 mM simvastatin with and without 2.5 mM mevalonate pretreatment, for the indicated time periods. Specific
antibodies were used as indicated to detect levels of LC3-II, and the cleavage of caspases-3. GAPDH was used as loading control. (B) Cell viability of
HASM cells measured following treatment with 10 mM simvastatin (Simva.) and/or 2.5 mM mevalonate (Mev.) as indicated. HASM were pretreated
4 hrs with indicated concentration of mevalonate and then co-treated for 96 hrs with simvastatin. Results are expressed as mean 6 SD of 9
independent experiments using three different sources (donors) of HASM cells. NS, not significant.
doi:10.1371/journal.pone.0016523.g002
Figure 1. Simvastatin induces autophagy in primary human airway smooth muscle (HASM) cells and human airway fibroblasts
(HAF). (A) HASM cells were either left untreated (top panel) or they were treated with 10 mM simvastatin (lower panels) for 72 hrs. Cells were then
imaged by TEM. Magnification: 4.6610
3. Structures identified as autophagosomes are indicated with black arrows. Lysosomes (ly), fused
autophagosomes and lysosomes (a-1 fusion) and late autophagolysosomes (al) are highlighted in magnified images of each cytosolic vesicle. The
scale bar represents 2 micron in all the top row and left panel in the middle. The scale bar in the right side panel in the middle row represents to 1
micron. The lower row shows enlarged images of ‘‘ly’’, ‘‘a-l fusion’’ and ‘‘al’’ regions highlighted by broken lines in the right hand panel of the middle
row. (B) Quantification of classic autophagosomes (exclusive of large lucent vesicles seen in low magnification images of Fig. 1A) in six different views
of TEM images in controls and simvastatin (10 mM, 72 hrs) treatments (with the same magnification) indicated significant difference of
autophagosome between control and treatment groups (P,0.001) (C) HASM treated with simvastatin (+Simva, 10 mM, 72 hrs) showed increased in
Lysotracker Red staining, a marker of lysosomal activation. (D) HASM treated with simvastatin (+Simva, 10 mM, 72 hrs) showed an increase in
punctuate staining for LC3-b (green), a marker of autophagy. (E) Quantification of LC3b puncta in six different views of immunofluorescence images
in controls and simvastatin (10 mM, 72 hrs) treatments (with the same magnification) indicated significant difference of LC3b puncta between control
and treatment groups (P,0.001) (F) HASM cells treated with simvastatin showed an increase in co-localization of Lysotracker Red and LC3-b (green),
indicating the fusion of lysosome and autophagosome to form an autophagolysosome. (G) Western blot analysis of cell lysates from HASM and HAF.
Cells were treated with 10 mM simvastatin for the indicated time periods, and then immunoblotted using the indicated specific antibodies. BNIP3
appears as both a monomer (30 kDa) and a dimer (60 kDa). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. (H)
Densitometry analysis of LC3 II formation in HASM and HAF. Data represent means 6 s.e. mean of three independent experiments, using 3 different
cell lines. For each experiment LC3 II compared to control, and GAPDH was used as a loading control.
doi:10.1371/journal.pone.0016523.g001
p53 in Protein Lipidation Controlled Cell Death
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16523p53 in Protein Lipidation Controlled Cell Death
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16523induced apoptosis and found that silencing of p53 or treatment
with pifithrin-a inhibited PUMA and NOXA induction with
parallel inhibition of caspase-3 and -7 cleavage (Fig. 6D–F and I–
K). In concert, we also assessed the impact of p53 inhibition on
autophagy markers and observed that DRAM expression, Atg5-12
complex formation, and LC3-b II formation was reduced
(Figs. 6G,H, L–N). These data show that both apoptosis and
autophagy induced by mevalonate cascade inhibition are regulat-
ed by p53. Thus, p53 plays a dual role, being required for both
simvastatin-induced autophagy and apoptosis.
Discussion
We have reported that inhibition of the mevalonate cascade in
primary human HASM and HAF induces apoptosis via a novel
p53-dependent pathway which involves inhibition of small Rho-
GTPase anchorage to the cytoplasmic membrane without
changing total cellular cholesterol content [13]. We now extend
these findings and show that concurrent with apoptosis, mevalo-
nate cascade suppression by HMG-CoA reductase inhibition
induces an early p53-dependent autophagic response that appears
to be a mechanism for quenching rapid apoptotic cell death that
results from simvastatin-induced cell stress. An increasing body of
evidence supports the existence of cross-talk between apoptosis
and autophagy, including both positive and negative interactions
[7,8,13,41,42,43]. To our knowledge, this is the first report
highlighting the interplay between autophagy and apoptosis
during conditions that inhibit protein lipidation cascades that
regulate intracellular signaling.
Autophagy has been viewed both as a cell-survival, and as a cell
death response, but discriminating both roles is difficult in some
experimental systems [44]. The existence of autophagic vesicles in
dying cells may suggest a causal relationship between autophagy
and cell death [45,46], or it may represent remnants from an
initial adaptive reaction to support cell survival under stress
[47,48]. In the present study, co-treatment of HASM and HAF
with the autophagy inhibitors 3-MA, and Baf-A1 markedly
increased simvastatin-induced activation of caspase-3 and -7 and
cell death, suggesting a protective (pro-survival) role for autoph-
agy. A protective role for autophagy is further supported by our
observation that simvastatin-induced cell death was significantly
increased in HASM cells in which the Atg5 expression had been
silenced. Furthermore, Atg5 silencing was associated with
increased activity of caspase-3, -7 and also PARP cleavage upon
simvastatin treatment. The protective role for autophagy against
simvastatin-induced cell death suggests that autophagy is an
important physiological pro-survival process under stress condi-
tions induced by inhibiting synthesis of isoprenoid lipid anchors
required for activation of small GTPases.
LC3 lipidation is currently one of the most reliable markers of
autophagosome formation in mammalian cells, where the relative
amount of LC3-II reflects autophagosome abundance [7,29].
Autophagic cells are also characterized biochemically by the
presence of cleaved LC3, and its punctuate redistribution inside
the cell [7]. We observed punctuate pattern of LC3-distribution in
human airway mesenchymal cells, upon treatment with simvasta-
tin, and it colocalized to lysosomes. In mammalian cells,
autophagosomes form in the cytosol and then they fuse with
lysosomes for degradation [29]. Both processes are influenced by
distinct control mechanisms [7,29]. Cellular LC3-II correlates
with autophagosome number in mammalian cells [29], whereas an
increase in the level of LC3-bII, as observed in our study upon
simvastatin treatment, is mostly a result of enhanced autophago-
somal formation, inhibited autophagosomal degradation, or a
combination of the two [29]. In the present study, we observed
that pretreatment with 3-MA was associated with a decrease in
simvastatin-induced LC3-bII formation in airway mesenchymal
cells, essentially reversing the effect of simvastatin and blocking
autophagy. In contrast, pretreatment with the vacuole H
+-ATPase
inhibitor Baf-A1, which blocks later autophagosomal degradation,
increased the formation of LC3-bII in simvastatin-treated airway
mesenchymal cells up to 72 hrs after treatment. These studies
suggest that simvastatin induces autophagy by enhancing the
synthesis of autophagosomes. Notably, the use of Baf-A1 resulted
in a corresponding increase in caspase-3, -7, and -9 cleavage and
activation, indicating increased apoptotic signaling. We thus
conclude that simvastatin-induced autophagy in human airway
mesenchymal cells involves enhanced autophagosomal synthesis
and may be a modulator mechanism for apoptosis.
We and others have shown that simvastatin-induced apoptosis
can be reversed by the downstream product, mevalonate,
demonstrating that simvastatin’s action is mediated by changes
in protein prenylation [13,49,50]. In the present study, we showed
that simvastatin-induced autophagy was inhibited by mevalonate
co-treatment, confirming that mevalonate cascade inhibition could
induce both apoptosis and autophagy. We have previously shown
that apoptosis triggered by mevalonate cascade inhibition is p53-
dependent [13]. In those experiments, simvastatin increased the
expression of PUMA and NOXA, as well as the translocation of
these proteins to mitochondria [13]. Others observed a similar
involvement of p53 in the inhibition of cell proliferation in
different cell types [51,52]. The present study extends our previous
work and demonstrates a role for p53 in simvastatin-induced
autophagy, and the interplay between autophagy and apoptosis
upon simvastatin treatment. The use of either pifithrin-a or p53
shRNAi significantly inhibited simvastatin-induced cell death in
HASM. There are several reports indicating that p53 regulates
autophagy in other biologic systems [6,8,12,14,53]. For example,
p53 activation-induced autophagy may be mediated by transacti-
vation of autophagy inducers such as DRAM [6]. In this study we
show by immunoblotting and qRT-PCR that simvastatin
treatment induced DRAM expression in HASM cells, along with
Figure 3. Autophagy inhibition increases simvastatin-induced cell death in HASM and HAF. (A&B) Side by side comparison of simvastatin-
induced apoptosis (sub-G1 population of the cells) and autophagy (LC3 II formation) in HASM and HAF. Mevalonate cascade inhibition induced an early
autophagy responseandlater apoptotic response. Ateach time pointLC3-II level relative to itstime matched control arenormalized with time zero LC3-
II levels to highlight temporal trends. Data represent means 6 s.e. mean of three independent experiments, using 3 different cell lines. Cell viability was
measured in cultured HASM and HAF after treatment with 10 mM simvastatin for 96 hrs with and without pretreatment with the following inhibitors of
autophagy: (C, E) 1.25 or 2.5 mM 3-MA; (D, F) 0.01 or 0.02 mM Baf-A1. Results are expressed as percentage of corresponding time point control and
represent the means 6 SD of 12 independent experiments in three different sets of donor-matched HASM and HAF **, P,0.01; ***, P,0.001. (G)H A S M
cells co-treated with 10 mM simvastatin for 48 hrs with and without 0.02 mM Baf-A1, photographed under phase contrast microscopy settings. Arrows
indicates partially detached cells with condensed morphology.(H) Baf-A1 enhanced LC3-II level in simvastatin treated cells. HASM were treated with
simvastatin (10 mM) in indicated time points in presence and absence of Baf-A1. Baf-A1-simvastatin increased LC3-II level compared to simvastatin
treatment. (I) 3-MA decreased LC3-II level in simvastatin treated cells. HASM were treated with simvastatin (10 mM) in indicated time points in presence
and absence of 3-MA. 3-MA-simvastatin increased LC3-II level compared to simvastatin treatment.
doi:10.1371/journal.pone.0016523.g003
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tion of p53 with either pifithrin-a or p53-shRNAi resulted in the
loss of simvastatin-induced PUMA, NOXA and DRAM expres-
sion followed by reduced caspase cleavage (marker of apoptosis)
and LC3-II formation (marker of autophagy) compared to wild
type or scramble shRNAi infected cells treated with simvastatin.
Others have reported a cellular localization-dependence effect of
p53: cytosolic p53 would inhibit autophagy while nuclear p53 is
pro-autophagic [12]. Our results showed that simvastatin
treatment provoked p53 translocation to nucleus. Thus, our data
is in agreement with recent findings that nuclear p53 can induce
both autophagy and apoptosis through transcriptional effects [12].
It has been previously reported that depolarized mitochondria
are rapidly eliminated by autophagy in primary hepatocytes,
leading to the hypothesis that autophagy may protect against
apoptosis by increasing the threshold of mitochondria-dependent
cell death [54]. In this model, elimination of damaged mitochon-
dria by autophagy might prevent the release of proapoptotic
signals from mitochondria [55]. In the absence of this scavenging
process, the release of reactive oxygen species from damaged
Figure 4. Autophagy inhibition increases apoptosis in HASM and HAF treated with simvastatin. (A, B). HASM were pretreated with
0.02 mM Baf-A1 in combination with 10 mM simvastatin for 96 hrs and the sub-G1 population was quantified using the Nicoletti method. Results
shown are mean 6 SD of 3 independent experiments in HASM primary cell lines from two different donors. **, P,0.01, compared to time-matched
control. (B&C) Measurement of caspase activity in HASM and HAF co-treated with 10 mM simvastatin and 0.02 mM Baf-A1. Caspase-3/-7 activity were
measured in treated cells at the indicated time points and compared to time-matched controls. ***, P,0.001. (D) Protein immunoblots used to access
levels of cleaved caspases as well as the appearance of LC3-II in HASM treated with 10 mM simvastatin and 0.02 mM Baf-A1, for the indicated time
periods. Detection of GAPDH served as a loading control.
doi:10.1371/journal.pone.0016523.g004
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necrotic cell death. In our experimental system, inhibition of
simvastatin-induced autophagy enhanced simultaneously-occur-
ring apoptotic cell death pathways. It is unclear whether
autophagic elimination of depolarized mitochondria may be
stimulated by mevalonate cascade inhibition, but a number of
reports by us and others have revealed that mitochondrial ROS
production can be induced by statin exposure in vitro [13,56,57].
The data presented here show that mevalonate cascade
inhibition in human airway mensenchymal cells leads to activation
of both apoptotic and autophagic responses, with the latter effect
occurring more rapidly and counteracting the former for a finite
duration; in other words, p53-induced autophagy appears to be a
negative regulator of p53-induced apoptosis. Our data also
indicate that both direct mechanisms (p53-dependent upregulation
of DRAM), as well as indirect effects (i.e. BNIP3-mediated reversal
Figure 5. Inhibition of Atg5 and Atg7 by specific shRNAi resulted in an increase of cell death in simvastatin-treated HASM.
(A) Protein immunoblotting demonstrate that ATG5 shRNAi significantly inhibited Atg5-12 complex formation. Scrambled sequence was used as an
RNAi control. (B) Protein immunoblotting of simvastin-treated HASM, both control and ATG5 shRNAi. Specific antibodies against the indicated
proteins were used, with GAPDH serving a loading control. (C) Cell viability assay (MTT assay) using control and ATG5 shRNAi HASM cells, with and
without simvastatin treatment (10 mM, 96 hrs) showed that ATG5 shRNAi significantly increased simvastatin induced cell death (P,0.05). (D) Protein
immunoblot demonstrating that ATG7 shRNAi significantly inhibited Atg7 expression. Scrambled sequence was used as an RNAi control.
(E) Immunoblotting of simvastatin-treated HASM after infection with lentivirus harboring control or ATG7 shRNAi. Specific antibodies against the
indicated proteins were used, with GAPDH serving a loading control. (F) Cell viability assay (MTT assay) using control and ATG7 shRNAi HASM cells,
with and without simvastatin treatment (10 mM, 96 hrs) showed that ATG7 shRNAi significantly increased simvastatin induced cell death (P,0.01).
doi:10.1371/journal.pone.0016523.g005
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16523Figure 6. Simvastatin-induced apoptosis and autophagy are mediated via p53-dependent pathway. (A) Cell viability assay carried out
on cells transduced with shRNAi targetting p53 or scrambled sequence as a control, with and without treatment with 10 mM simvastatin for 96 hours.
Results are expressed as percentage of corresponding control and represent mean 6 SD of 6 independent experiments (**: P,0.01). (B) HASM
assesses using MTT assay. Cell viability was measured by comparing each treatment with corresponding control. Results reflect mean 6 SD of four
independent experiments (* * *: P,0.001). (C) Immunoblotting of cytosolic (Cyt) and nuclear (Nuc) extracts from HASM cells treated with 10 mM
simvastatin for the indicated time points, using p53 antibody to detect nuclear translocation. HASM were treated with simvastatin (10 mM) for
indicated time points (0–96 hrs). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and histone deacetylase 1 (HDAC1) were used as loading
p53 in Protein Lipidation Controlled Cell Death
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foundation of p53-proautophagic effect triggered by simvastatin.
Supporting Information
Figure S1 Simvastatin induces apoptosis in primary
human away smooth muscle (HASM) cells and airway
fibroblasts (HAF). (A) The cells were treated with simvastatin
(10 mM) and cell viability was assessed 48 and 96 hrs thereafter by
MTT assay. Control cells for each time point were treated with the
solvent control (DMSO). Results are expressed as percentage of
corresponding time point control and represent the means 6 SD
of 12 independent experiments in three different sets of patient-
matched HASM and HAF (**, P,0.01; ***, P,0.001). (B) HASM
and HAF cells were treated with simvastatin (10 mM) and at the
indicated time points apoptosis was measured using Nicolleti
method (see materials and methods). Percent sub-G1 HASM and
HAF abundance induced by simvastatin or DMSO solvent control
after 48 and 96 hrs. Results represent the means 6 SD of 6
independent experiments in two different patient-matched HASM
and HAF primary cell lines. **, P,0.01; and ***, P,0.001
compared to time-matched control. (C) Effects of simvastatin (10
mM) treatment (24 and 72 hrs) on caspase-3/-7, and caspase-9
enzymatic activity, as detected by Caspase-GloH luminometric
assay. Caspase activity normalized to that measured for solvent-
only treated cultures is represented on the Y-axis. The data
represent mean 6 SD of duplicate experiments performed on 4
different patient-matched primary HASM and HAF cell lines.
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